Increasing Funding/investment for Liquid Biopsy is a Key Trend Gaining Market Momentum
1h Free Analyst Time
The global liquid biopsy market is forecasted to grow by USD 2.16 billion during 2022-2027, accelerating at a CAGR of 19.54% during the forecast period. The market is driven by the increasing incidence of cancer, the growing focus on personalized medicine for cancer care, and advancements in liquid biopsy technologies.Speak directly to the analyst to clarify any post sales queries you may have.
This report on the liquid biopsy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.
The global liquid biopsy market is segmented as below:
By Application
- Cancer applications
- Non-cancer applications
By Technology
- CTC and ctDNA
- Exosome and RNA
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the liquid biopsy market covers the following areas:
- Liquid biopsy market sizing
- Liquid biopsy market forecast
- Liquid biopsy market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Technology
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The research team recognizes the following companies as the key players in the global liquid biopsy market: A. Menarini Industrie Farmaceutiche Riunite Srl, ANGLE Plc, Bio Rad Laboratories Inc., Bio Techne Corp., Biocept Inc., Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corp., F. Hoffmann La Roche Ltd., Guardant Health Inc., Illumina Inc., Inivata Ltd., MDXHEALTH SA, Mesa Laboratories Inc., Myriad Genetics Inc., Novogene Co. Ltd., OncoCyte Corp., QIAGEN NV, and SAGA Diagnostics AB.One of the report's analysts commented on the report, saying: 'The latest trend gaining momentum in the market is increasing funding/investment for liquid biopsy.'
According to the report, one of the major drivers for this market is the increasing incidence of cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- ANGLE PLC
- Bio Rad Laboratories Inc.
- Bio Techne Corp.
- Biocept Inc.
- Biodesix Inc.
- CellMax Inc.
- CIRCULOGENE
- Exact Sciences Corp.
- F. Hoffmann La Roche Ltd.
- Guardant Health Inc.
- Illumina Inc.
- Inivata Ltd.
- MDXHEALTH SA
- Mesa Laboratories Inc.
- Myriad Genetics Inc.
- Novogene Co. Ltd.
- OncoCyte Corp.
- QIAGEN NV
- SAGA Diagnostics AB
